Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.57, No.3, p.241-246, 2010 |
||
| Title: Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (Stage III and IV) non-small cell lung cancer | ||
| Author: Y. S. Kim, M. K. Lee, S. J. Kim, I. J. Kim, Y. K. Kim, W. S. Jo, S. K. Park | ||
| Abstract: F-18 FDG PET could provide prognostic information in patients with advanced resectable NSCLC. In the current study, we investigated the prognostic implication of F-18 FDG PET after chemotherapy in patients with advanced stage III and IV NSCLC. A retrospective review identified 19 patients with advanced stage (stage III and IV) NSCLC who received F-18 FDG PET/CT at diagnosis of cancer and after chemotherapy. The visual response and changes of SUV max before and after treatment on survival was investigated using Kaplan-Meier and Cox proportional hazard regression analyses. The median follow-up time was overall 24.8 month (range, 9.4~59.8 month), for surviving patients 41 month (range, 34.1~59.8 month), and for deceased patients 16.6 month (range, 9.4~29.4 month). Overall survival after baseline F-18 FDG PET/CT at 1 year was 73.7% and at 2 year was 47.4%. Comparing patients with and without F-18 FDG PET/CT response, there was statistically significant difference in overall survival between the 2 groups (median survival time, responder, 29.4 month; non-responder, 14.2 month, Χ2=3.91, p=0.048). Also, using the %ΔSUVmax for the comparison, significant difference was existed in overall survival between 2 groups (Χ2=12.6, p=0.0004). When the tumor reveals more than 17.85% reduction of %ΔSUVmax, the survival could be predicted (AUC, 0857; standard error, 0.0866; 95% confidence interval, 0.622~0.971; sensitivity, 75%; specificity, 100%; p=0.0001). With Cox proportional hazard model, %ΔSUVmax was determined to be a potent prognostic factor for survival (Χ2, 12.09; p=0.0005). In conclusion, using the visual and quantitative analyses of F-18 FDG PET/CT, the responder to chemotherapy in advanced stage NSCLC patients had a better prognosis. Moreover, the potent predictor of prognosis in advanced stage NSCLC patients was %ΔSUVmax. |
||
| Keywords: Non-small cell lung cancer, F-18 FDG PET/CT, survival, chemotherapy | ||
| Year: 2010, Volume: 57, Issue: 3 | Page From: 241, Page To: 246 | |
| doi:10.4149/neo_2010_03_241 |
||
|
|
 download file |
|